Researcher Aims to Advance Immunotherapy Impact in Bladder Cancer – OncLive
OncLive |
Researcher Aims to Advance Immunotherapy Impact in Bladder Cancer
OncLive Immunotherapy agents may be taking the field of urothelial cancer by storm, according to Arlene O. Siefker-Radtke, MD, but the therapies are still only responding in 15% to 25% of patients. “Clearly, immune checkpoint inhibition is here to stay,” says … |
